A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical.

Slides:

Advertisements

Similar presentations

Auditory nerve disease and auditory neuropathy spectrum disorders Kimitaka Kaga Auris Nasus Larynx Volume 43, Issue 1, Pages (February 2016) DOI:

Advertisements

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised,placebo-controlled.

Perimenopausal migraine in women with vasomotor symptoms E. Anne MacGregor Maturitas Volume 71, Issue 1, Pages (January 2012) DOI: /j.maturitas

The most efficient STR loci in forensic genetics in population of central Poland R. Jacewicz, M. Jedrzejczyk, J. Berent Forensic Science International:

The Survival Kit: Software to analyze survival data including possibly correlated random effects G. Mészáros, J. Sölkner, V. Ducrocq Computer Methods and.

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Combined estrogen–progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats L.A. Olatunji,

Eribulin—A review of preclinical and clinical studies

Effects of plant stanol esters on serum cholesterol concentrations, relative markers of cholesterol metabolism and endothelial function in type 1 diabetes

Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi

Early childhood hospitalisation with infection and subclinical atherosclerosis in adulthood: The Cardiovascular Risk in Young Finns Study David P. Burgner,

The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals Maartje Verschuur, Annemarie.

A comparison of AmpFlSTR Identifiler™ Kit versus AmpFlSTR Identifiler Plus™ Kit in challenging bone samples by using normal and increased PCR cycle number

Volume 357, Issue 9273, Pages (June 2001)

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high- density lipoprotein-cholesterol: Randomized comparison of fenofibrate.

Does statin therapy reduce plasma VEGF levels in humans

Early childhood hospitalisation with infection and subclinical atherosclerosis in adulthood: The Cardiovascular Risk in Young Finns Study David P. Burgner,

S. Böhler, H. Scharnagl, F. Freisinger, T. Stojakovic, H. Glaesmer, J

LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia Ilker Tasci, Gokhan Erdem, Gokhan Ozgur, Serkan Tapan, Teoman Dogru,

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Maros Ferencik, Yiannis S. Chatzizisis Atherosclerosis

Treatment of Primary Varicose Veins by Endovenous Obliteration with the VNUS Closure System: Results of a Prospective Multicentre Study Ph. Nicolini,

Is ginger effective for the treatment of irritable bowel syndrome

The effectiveness of Swedish massage with aromatic ginger oil in treating chronic low back pain in older adults: A randomized controlled trial Netchanok.

A randomised clinical trial of routine versus selective CT imaging in acute abdomen: Impact of patient age on treatment costs and hospital resource use

Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects Stefano Rizza, Marina Cardellini, Ottavia Porzio, Chiara.

Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration Damien Denimal, Jean-Paul.

Establishing the benefit of statins in low-to-moderate—risk primary prevention: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Critical Reviews in Oncology / Hematology

Volume 21, Issue 2, Pages (June 2014)

A comparison of AmpFlSTR Identifiler™ Kit versus AmpFlSTR Identifiler Plus™ Kit in challenging bone samples by using normal and increased PCR cycle number

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs? Raul D. Santos Atherosclerosis.

Meta-analysis of randomised controlled trials

Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats Mehrdad Roghani, Tourandokht.

Volume 21, Issue 1, Pages (February 2014)

Oxidative stress in autism

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Think Again About Cholesterol Survey

Marina Cuchel, Dirk J. Blom, Maurizio R. Averna

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Volume 21, Issue 2, Pages (June 2014)

C. Davies, J. Thomson, F. Kennedy

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group,

An assessment by the Statin Intolerance Panel: 2014 update

Establishment of Italian national DNA database and the central laboratory: Some aspects R. Biondo, F. De Stefano Forensic Science International: Genetics.

Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia Francesco A. Aiello, MD, Asad A.

Nicholas D. James, Jim W. Growcott European Urology Supplements

R. Alghafri, S. Alhammadi, K. Amiri

Population data for SE33 locus in United Arab Emirates Arab population

MRC/BHF Heart Protection Study

Manuela Casula, Alberico L

Christina Valgren, Sara Wester, Oskar Hansson

Confessions of a journal junkie

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.

Current concepts in the surgical approach to necrotizing enterocolitis

Combining DNA evidence for greater match information

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Automated addition of Chelex solution to tubes containing trace items

David A. Clark, Upender K. Munshi Pathophysiology

A comparison of AmpFlSTR Identifiler™ Kit versus AmpFlSTR Identifiler Plus™ Kit in challenging bone samples by using normal and increased PCR cycle number

Application of less primer method to commercial kits

Pitavastatin and HDL: Effects on plasma levels and function(s)

Low dietary folate impairs glucose tolerance and plasma lipid profile in oral contraceptive-treated rats L.A. Olatunji, A.O. Soladoye Pathophysiology

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,

Proteinase K challenged by a novel protease

Presentation transcript:

A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence Vivencio Barrios, Carlos Escobar, Arrigo Francesco Giuseppe Cicero, David Burke, Peter Fasching, Maciej Banach, Eric Bruckert Atherosclerosis Supplements Volume 24, Pages 1-15 (February 2017) DOI: 10.1016/j.atherosclerosissup.2016.10.003 Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Complementary mechanisms of Armolipid Plus containing red yeast rice, policosanol, berberine, folic acid, astaxanthin, and coenzyme Q10. Atherosclerosis Supplements 2017 24, 1-15DOI: (10.1016/j.atherosclerosissup.2016.10.003) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Mean plasma concentrations for berberine (A) and lovastatin hydroxyl acid (B). SD are shown with vertical bar [38, modified]. Atherosclerosis Supplements 2017 24, 1-15DOI: (10.1016/j.atherosclerosissup.2016.10.003) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

Fig. 3 A. Comparison between Armolipid Plus and ezetimibe (10 mg daily) in 228 patients with primary hypercholesterolemia and intolerance to statins (22%) or refusal to take them (78%) within the setting of a 6-month randomized controlled clinical trial (p-values are for comparison between groups). B. Results of the treatment of 26 patients in whom monotherapy with Armolipid Plus (n = 14) or ezetimibe (10 mg daily) had failed (reduction in LDL-C plasma levels <29%) for another 3 months with the combination of Armolipid Plus + ezetimibe [53] (p-values are for comparison between the association of Armolipid Plus + ezetimibe and the single administration of the 2 compounds). Atherosclerosis Supplements 2017 24, 1-15DOI: (10.1016/j.atherosclerosissup.2016.10.003) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

Fig. 4 Variations in the primary endpoint (A) and in secondary endpoints (B) [44]. HOMA: Homeostasis model assessment; FMD: Flow-mediated dilation. Atherosclerosis Supplements 2017 24, 1-15DOI: (10.1016/j.atherosclerosissup.2016.10.003) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions